JP2023512302A - ステント、マンドレル、および移動防止特徴を有するステントを形成するための方法 - Google Patents
ステント、マンドレル、および移動防止特徴を有するステントを形成するための方法 Download PDFInfo
- Publication number
- JP2023512302A JP2023512302A JP2022547068A JP2022547068A JP2023512302A JP 2023512302 A JP2023512302 A JP 2023512302A JP 2022547068 A JP2022547068 A JP 2022547068A JP 2022547068 A JP2022547068 A JP 2022547068A JP 2023512302 A JP2023512302 A JP 2023512302A
- Authority
- JP
- Japan
- Prior art keywords
- filaments
- medical stent
- cylinder
- protrusions
- mandrel
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000013508 migration Methods 0.000 title claims description 82
- 238000000034 method Methods 0.000 title claims description 13
- 238000004804 winding Methods 0.000 claims description 14
- 238000004519 manufacturing process Methods 0.000 claims description 4
- -1 polytetrafluoroethylene Polymers 0.000 description 13
- 239000000463 material Substances 0.000 description 12
- 238000000576 coating method Methods 0.000 description 10
- 239000011248 coating agent Substances 0.000 description 9
- 229910001182 Mo alloy Inorganic materials 0.000 description 7
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 6
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 4
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 4
- 239000003146 anticoagulant agent Substances 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 239000003102 growth factor Substances 0.000 description 4
- 229910000856 hastalloy Inorganic materials 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 229920000106 Liquid crystal polymer Polymers 0.000 description 3
- 239000004977 Liquid-crystal polymers (LCPs) Substances 0.000 description 3
- 239000004952 Polyamide Substances 0.000 description 3
- 229920002614 Polyether block amide Polymers 0.000 description 3
- 239000004721 Polyphenylene oxide Substances 0.000 description 3
- 229910045601 alloy Inorganic materials 0.000 description 3
- 239000000956 alloy Substances 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 238000002595 magnetic resonance imaging Methods 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- 150000002739 metals Chemical class 0.000 description 3
- 229910001000 nickel titanium Inorganic materials 0.000 description 3
- 229910052697 platinum Inorganic materials 0.000 description 3
- 229920002647 polyamide Polymers 0.000 description 3
- 229920002635 polyurethane Polymers 0.000 description 3
- 239000004814 polyurethane Substances 0.000 description 3
- 229910001220 stainless steel Inorganic materials 0.000 description 3
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 2
- 229910000881 Cu alloy Inorganic materials 0.000 description 2
- 229940123011 Growth factor receptor antagonist Drugs 0.000 description 2
- 229920000339 Marlex Polymers 0.000 description 2
- 239000004696 Poly ether ether ketone Substances 0.000 description 2
- 239000004697 Polyetherimide Substances 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- 239000004642 Polyimide Substances 0.000 description 2
- 239000004734 Polyphenylene sulfide Substances 0.000 description 2
- 239000004743 Polypropylene Substances 0.000 description 2
- 229910001080 W alloy Inorganic materials 0.000 description 2
- 229960001138 acetylsalicylic acid Drugs 0.000 description 2
- 230000000702 anti-platelet effect Effects 0.000 description 2
- 230000001028 anti-proliverative effect Effects 0.000 description 2
- 239000004019 antithrombin Chemical class 0.000 description 2
- 230000001588 bifunctional effect Effects 0.000 description 2
- 239000012620 biological material Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000000788 chromium alloy Substances 0.000 description 2
- PRQRQKBNBXPISG-UHFFFAOYSA-N chromium cobalt molybdenum nickel Chemical compound [Cr].[Co].[Ni].[Mo] PRQRQKBNBXPISG-UHFFFAOYSA-N 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- YOCUPQPZWBBYIX-UHFFFAOYSA-N copper nickel Chemical compound [Ni].[Cu] YOCUPQPZWBBYIX-UHFFFAOYSA-N 0.000 description 2
- 231100000599 cytotoxic agent Toxicity 0.000 description 2
- 239000002619 cytotoxin Substances 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229910000701 elgiloys (Co-Cr-Ni Alloy) Inorganic materials 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 150000002170 ethers Chemical class 0.000 description 2
- 229920000840 ethylene tetrafluoroethylene copolymer Polymers 0.000 description 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
- 229910052737 gold Inorganic materials 0.000 description 2
- 239000010931 gold Substances 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 229910001092 metal group alloy Inorganic materials 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- DDTIGTPWGISMKL-UHFFFAOYSA-N molybdenum nickel Chemical compound [Ni].[Mo] DDTIGTPWGISMKL-UHFFFAOYSA-N 0.000 description 2
- HLXZNVUGXRDIFK-UHFFFAOYSA-N nickel titanium Chemical compound [Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni] HLXZNVUGXRDIFK-UHFFFAOYSA-N 0.000 description 2
- 229910052763 palladium Inorganic materials 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 2
- 229920001707 polybutylene terephthalate Polymers 0.000 description 2
- 229920000728 polyester Polymers 0.000 description 2
- 229920002530 polyetherether ketone Polymers 0.000 description 2
- 229920001601 polyetherimide Polymers 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- 229920000139 polyethylene terephthalate Polymers 0.000 description 2
- 239000005020 polyethylene terephthalate Substances 0.000 description 2
- 229920001721 polyimide Polymers 0.000 description 2
- 229920006324 polyoxymethylene Polymers 0.000 description 2
- 229920006380 polyphenylene oxide Polymers 0.000 description 2
- 229920000069 polyphenylene sulfide Polymers 0.000 description 2
- 229920001155 polypropylene Polymers 0.000 description 2
- 229920001296 polysiloxane Polymers 0.000 description 2
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 2
- 239000004810 polytetrafluoroethylene Substances 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 210000005167 vascular cell Anatomy 0.000 description 2
- KWPACVJPAFGBEQ-IKGGRYGDSA-N (2s)-1-[(2r)-2-amino-3-phenylpropanoyl]-n-[(3s)-1-chloro-6-(diaminomethylideneamino)-2-oxohexan-3-yl]pyrrolidine-2-carboxamide Chemical compound C([C@@H](N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)CCl)C1=CC=CC=C1 KWPACVJPAFGBEQ-IKGGRYGDSA-N 0.000 description 1
- PUDHBTGHUJUUFI-SCTWWAJVSA-N (4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-n-[(2s,3r)-1-amino-3-hydroxy-1-oxobutan-2-yl]-19-[[(2r)-2-amino-3-naphthalen-2-ylpropanoyl]amino]-16-[(4-hydroxyphenyl)methyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-7-propan-2-yl-1,2-dithia-5,8,11,14,17-p Chemical compound C([C@H]1C(=O)N[C@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](N)CC=1C=C2C=CC=CC2=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(N)=O)=O)C(C)C)C1=CC=C(O)C=C1 PUDHBTGHUJUUFI-SCTWWAJVSA-N 0.000 description 1
- ZKMNUMMKYBVTFN-HNNXBMFYSA-N (S)-ropivacaine Chemical compound CCCN1CCCC[C@H]1C(=O)NC1=C(C)C=CC=C1C ZKMNUMMKYBVTFN-HNNXBMFYSA-N 0.000 description 1
- KHXKESCWFMPTFT-UHFFFAOYSA-N 1,1,1,2,2,3,3-heptafluoro-3-(1,2,2-trifluoroethenoxy)propane Chemical compound FC(F)=C(F)OC(F)(F)C(F)(F)C(F)(F)F KHXKESCWFMPTFT-UHFFFAOYSA-N 0.000 description 1
- LEBVLXFERQHONN-UHFFFAOYSA-N 1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide Chemical compound CCCCN1CCCCC1C(=O)NC1=C(C)C=CC=C1C LEBVLXFERQHONN-UHFFFAOYSA-N 0.000 description 1
- VNDNKFJKUBLYQB-UHFFFAOYSA-N 2-(4-amino-6-chloro-5-oxohexyl)guanidine Chemical compound ClCC(=O)C(N)CCCN=C(N)N VNDNKFJKUBLYQB-UHFFFAOYSA-N 0.000 description 1
- 102400000068 Angiostatin Human genes 0.000 description 1
- 108010079709 Angiostatins Proteins 0.000 description 1
- IYMAXBFPHPZYIK-BQBZGAKWSA-N Arg-Gly-Asp Chemical compound NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O IYMAXBFPHPZYIK-BQBZGAKWSA-N 0.000 description 1
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 description 1
- 229910000531 Co alloy Inorganic materials 0.000 description 1
- 229910000684 Cobalt-chrome Inorganic materials 0.000 description 1
- OMFXVFTZEKFJBZ-UHFFFAOYSA-N Corticosterone Natural products O=C1CCC2(C)C3C(O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 OMFXVFTZEKFJBZ-UHFFFAOYSA-N 0.000 description 1
- 206010011878 Deafness Diseases 0.000 description 1
- 229920004943 Delrin® Polymers 0.000 description 1
- 229920006055 Durethan® Polymers 0.000 description 1
- 102400001047 Endostatin Human genes 0.000 description 1
- 108010079505 Endostatins Proteins 0.000 description 1
- 239000004593 Epoxy Substances 0.000 description 1
- 229920000219 Ethylene vinyl alcohol Polymers 0.000 description 1
- 229910000640 Fe alloy Inorganic materials 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- 229920003620 Grilon® Polymers 0.000 description 1
- 102000007625 Hirudins Human genes 0.000 description 1
- 108010007267 Hirudins Proteins 0.000 description 1
- UETNIIAIRMUTSM-UHFFFAOYSA-N Jacareubin Natural products CC1(C)OC2=CC3Oc4c(O)c(O)ccc4C(=O)C3C(=C2C=C1)O UETNIIAIRMUTSM-UHFFFAOYSA-N 0.000 description 1
- 229920000271 Kevlar® Polymers 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- JHWNWJKBPDFINM-UHFFFAOYSA-N Laurolactam Chemical compound O=C1CCCCCCCCCCCN1 JHWNWJKBPDFINM-UHFFFAOYSA-N 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- 229910000792 Monel Inorganic materials 0.000 description 1
- 229910000990 Ni alloy Inorganic materials 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 229920000299 Nylon 12 Polymers 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 1
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- QXZUUHYBWMWJHK-UHFFFAOYSA-N [Co].[Ni] Chemical compound [Co].[Ni] QXZUUHYBWMWJHK-UHFFFAOYSA-N 0.000 description 1
- WAIPAZQMEIHHTJ-UHFFFAOYSA-N [Cr].[Co] Chemical compound [Cr].[Co] WAIPAZQMEIHHTJ-UHFFFAOYSA-N 0.000 description 1
- MTHLBYMFGWSRME-UHFFFAOYSA-N [Cr].[Co].[Mo] Chemical compound [Cr].[Co].[Mo] MTHLBYMFGWSRME-UHFFFAOYSA-N 0.000 description 1
- HZEWFHLRYVTOIW-UHFFFAOYSA-N [Ti].[Ni] Chemical compound [Ti].[Ni] HZEWFHLRYVTOIW-UHFFFAOYSA-N 0.000 description 1
- 229940035674 anesthetics Drugs 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000002927 anti-mitotic effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000003529 anticholesteremic agent Substances 0.000 description 1
- 229940127226 anticholesterol agent Drugs 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 229960004676 antithrombotic agent Drugs 0.000 description 1
- 108010072041 arginyl-glycyl-aspartic acid Proteins 0.000 description 1
- FZCSTZYAHCUGEM-UHFFFAOYSA-N aspergillomarasmine B Natural products OC(=O)CNC(C(O)=O)CNC(C(O)=O)CC(O)=O FZCSTZYAHCUGEM-UHFFFAOYSA-N 0.000 description 1
- 210000000013 bile duct Anatomy 0.000 description 1
- 229920000249 biocompatible polymer Polymers 0.000 description 1
- 229960004436 budesonide Drugs 0.000 description 1
- 229960003150 bupivacaine Drugs 0.000 description 1
- 238000005266 casting Methods 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- OGSYQYXYGXIQFH-UHFFFAOYSA-N chromium molybdenum nickel Chemical compound [Cr].[Ni].[Mo] OGSYQYXYGXIQFH-UHFFFAOYSA-N 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 239000010952 cobalt-chrome Substances 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- OMFXVFTZEKFJBZ-HJTSIMOOSA-N corticosterone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@H](CC4)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OMFXVFTZEKFJBZ-HJTSIMOOSA-N 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 239000000806 elastomer Substances 0.000 description 1
- 229920006351 engineering plastic Polymers 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 229960000610 enoxaparin Drugs 0.000 description 1
- 229930013356 epothilone Natural products 0.000 description 1
- HESCAJZNRMSMJG-KKQRBIROSA-N epothilone A Chemical class C/C([C@@H]1C[C@@H]2O[C@@H]2CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(C)=N1 HESCAJZNRMSMJG-KKQRBIROSA-N 0.000 description 1
- JBKVHLHDHHXQEQ-UHFFFAOYSA-N epsilon-caprolactam Chemical compound O=C1CCCCCN1 JBKVHLHDHHXQEQ-UHFFFAOYSA-N 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 238000005530 etching Methods 0.000 description 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 1
- 239000005038 ethylene vinyl acetate Substances 0.000 description 1
- 239000004715 ethylene vinyl alcohol Substances 0.000 description 1
- 239000003302 ferromagnetic material Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 239000003966 growth inhibitor Substances 0.000 description 1
- 239000007952 growth promoter Substances 0.000 description 1
- 239000002628 heparin derivative Substances 0.000 description 1
- RZXDTJIXPSCHCI-UHFFFAOYSA-N hexa-1,5-diene-2,5-diol Chemical compound OC(=C)CCC(O)=C RZXDTJIXPSCHCI-UHFFFAOYSA-N 0.000 description 1
- 229920001903 high density polyethylene Polymers 0.000 description 1
- 239000004700 high-density polyethylene Substances 0.000 description 1
- WQPDUTSPKFMPDP-OUMQNGNKSA-N hirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(OS(O)(=O)=O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@H](C(NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N2)=O)CSSC1)C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)CSSC1)C(C)C)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 WQPDUTSPKFMPDP-OUMQNGNKSA-N 0.000 description 1
- 229940006607 hirudin Drugs 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 229910001026 inconel Inorganic materials 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000001746 injection moulding Methods 0.000 description 1
- UGKDIUIOSMUOAW-UHFFFAOYSA-N iron nickel Chemical compound [Fe].[Ni] UGKDIUIOSMUOAW-UHFFFAOYSA-N 0.000 description 1
- 108010021336 lanreotide Proteins 0.000 description 1
- 229960002437 lanreotide Drugs 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 229920000092 linear low density polyethylene Polymers 0.000 description 1
- 239000004707 linear low-density polyethylene Substances 0.000 description 1
- 229920001684 low density polyethylene Polymers 0.000 description 1
- 239000004702 low-density polyethylene Substances 0.000 description 1
- 238000003754 machining Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- KBOPZPXVLCULAV-UHFFFAOYSA-N mesalamine Chemical compound NC1=CC=C(O)C(C(O)=O)=C1 KBOPZPXVLCULAV-UHFFFAOYSA-N 0.000 description 1
- 229960004963 mesalazine Drugs 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 230000000394 mitotic effect Effects 0.000 description 1
- MOWMLACGTDMJRV-UHFFFAOYSA-N nickel tungsten Chemical compound [Ni].[W] MOWMLACGTDMJRV-UHFFFAOYSA-N 0.000 description 1
- 229910000623 nickel–chromium alloy Inorganic materials 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- VPRUMANMDWQMNF-UHFFFAOYSA-N phenylethane boronic acid Chemical compound OB(O)CCC1=CC=CC=C1 VPRUMANMDWQMNF-UHFFFAOYSA-N 0.000 description 1
- 125000005498 phthalate group Chemical class 0.000 description 1
- 239000000106 platelet aggregation inhibitor Substances 0.000 description 1
- 229920002492 poly(sulfone) Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 229920000570 polyether Polymers 0.000 description 1
- 239000011112 polyethylene naphthalate Substances 0.000 description 1
- 229920000098 polyolefin Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 229920002215 polytrimethylene terephthalate Polymers 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 239000005033 polyvinylidene chloride Substances 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 239000002089 prostaglandin antagonist Substances 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 229960001549 ropivacaine Drugs 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- NCEXYHBECQHGNR-QZQOTICOSA-N sulfasalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-QZQOTICOSA-N 0.000 description 1
- 229960001940 sulfasalazine Drugs 0.000 description 1
- NCEXYHBECQHGNR-UHFFFAOYSA-N sulfasalazine Natural products C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 description 1
- 229910052715 tantalum Inorganic materials 0.000 description 1
- GUVRBAGPIYLISA-UHFFFAOYSA-N tantalum atom Chemical compound [Ta] GUVRBAGPIYLISA-UHFFFAOYSA-N 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 125000000383 tetramethylene group Chemical group [H]C([H])([*:1])C([H])([H])C([H])([H])C([H])([H])[*:2] 0.000 description 1
- 239000003803 thymidine kinase inhibitor Substances 0.000 description 1
- 239000010936 titanium Substances 0.000 description 1
- 229910052719 titanium Inorganic materials 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 108091006106 transcriptional activators Proteins 0.000 description 1
- WFKWXMTUELFFGS-UHFFFAOYSA-N tungsten Chemical compound [W] WFKWXMTUELFFGS-UHFFFAOYSA-N 0.000 description 1
- 229910052721 tungsten Inorganic materials 0.000 description 1
- 239000010937 tungsten Substances 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 210000001635 urinary tract Anatomy 0.000 description 1
- 229960005356 urokinase Drugs 0.000 description 1
- 230000002227 vasoactive effect Effects 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/82—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/86—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure
- A61F2/88—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure the wire-like elements formed as helical or spiral coils
- A61F2/885—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure the wire-like elements formed as helical or spiral coils comprising a coil including a plurality of spiral or helical sections with alternate directions around a central axis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/82—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/86—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure
- A61F2/90—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/82—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/848—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents having means for fixation to the vessel wall, e.g. barbs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/95—Instruments specially adapted for placement or removal of stents or stent-grafts
- A61F2/9522—Means for mounting a stent or stent-graft onto or into a placement instrument
- A61F2/9526—Means for mounting a stent or stent-graft onto or into a placement instrument using a mandrel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/95—Instruments specially adapted for placement or removal of stents or stent-grafts
- A61F2002/9505—Instruments specially adapted for placement or removal of stents or stent-grafts having retaining means other than an outer sleeve, e.g. male-female connector between stent and instrument
- A61F2002/9511—Instruments specially adapted for placement or removal of stents or stent-grafts having retaining means other than an outer sleeve, e.g. male-female connector between stent and instrument the retaining means being filaments or wires
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2220/00—Fixations or connections for prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2220/0008—Fixation appliances for connecting prostheses to the body
- A61F2220/0016—Fixation appliances for connecting prostheses to the body with sharp anchoring protrusions, e.g. barbs, pins, spikes
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Transplantation (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Media Introduction/Drainage Providing Device (AREA)
- Prostheses (AREA)
- Materials For Medical Uses (AREA)
Abstract
Description
本明細書に開示される任意の例に加えてまたは代えて、移動防止ループの少なくとも一部分が、中心長手軸に対して実質的に垂直に配向される。
本明細書に開示される任意の例に加えてまたは代えて、複数の第1のフィラメントと複数の第2のフィラメントとを織り合わせることが、複数の交点を画定する。
本明細書に開示される任意の例に加えてまたは代えて、溝は、複数の第1のチャネルのうちの隣接する第1のチャネルを接続する。
本明細書に開示される任意の例に加えてまたは代えて、医療用ステントを製造する方法が、円筒体と、円筒体から径方向外方に延びる複数の突出部とを備えるマンドレルを使用する工程であって、複数の突出部は、第1の方向に円筒体の周りをらせん状に延びる複数の第1のチャネルと、第2の方向に円筒体の周りをらせん状に延びる複数の第2のチャネルとを画定し、複数の突出部のうちの少なくともいくつかには、円筒体の周りを周方向に延びる溝が形成されている、工程と、複数の第1のチャネル内でマンドレルの周りに複数の第1のフィラメントを巻き付け、複数の第2のチャネル内でマンドレルの周りに複数の第2のフィラメントを巻き付けて、複数の第1のフィラメントと複数の第2のフィラメントとが織り合わされて医療用ステントの本体を画定するようにする工程とを備え得る。複数の第1のフィラメントのうちの少なくともいくつかは、複数の突出部のうちの形成された溝を含む少なくともいくつかの上に巻き付けられ得る。
本明細書に開示される任意の例に加えてまたは代えて、複数の突出部のうちの少なくともいくつかに形成された溝は、円筒体の周りを周方向に延びる。
すべての数値は、本明細書において、明示されているかどうかにかかわらず、「約」という用語で修飾されていると想定される。数値の文脈において「約」という用語は、一般に、記載された値と同等である(例えば、同じ機能または結果を有する)と当業者が考える数の範囲を指す。多くの場合、「約」という用語は、最も近い有効数字に丸められる数を含み得る。「約」という用語のその他の(例えば、数値以外の文脈における)使用は、別段に指定されない限り、明細書の文脈から理解され、それと整合するように、それらの通常の慣例的な定義を有すると想定されてよい。
Claims (15)
- 第1の端部と、第2の端部と、前記第1の端部から前記第2の端部まで延びる中心長手軸とを有する医療用ステントであって、
それぞれが第1の方向に前記中心長手軸の周りを第1のらせん状経路で延びる複数の第1のフィラメントと、
それぞれが第2の方向に前記中心長手軸の周りを第2のらせん状経路で延びる複数の第2のフィラメントと
を備え、
前記複数の第1のフィラメントは、前記複数の第2のフィラメントと織り合わされ、
前記複数の第1のフィラメントのうちの少なくとも1つの前記第1のらせん状経路は、前記第1の端部と前記第2の端部との間に配置された周方向オフセットを含む、医療用ステント。 - 前記複数の第1のフィラメントのうちの前記少なくとも1つは、前記周方向オフセットで前記医療用ステントの外面から径方向外方に突出する移動防止ループを含む、請求項1に記載の医療用ステント。
- 前記周方向オフセットが前記移動防止ループを形成する、請求項2に記載の医療用ステント。
- 前記移動防止ループの少なくとも一部分が、前記中心長手軸に対して実質的に垂直に配向される、請求項2または3に記載の医療用ステント。
- 前記移動防止ループの一部分が、前記医療用ステントの前記第1の端部または前記第2の端部に向かって角度を付けられる、請求項4に記載の医療用ステント。
- 前記複数の第1のフィラメントと前記複数の第2のフィラメントとを織り合わせることが、複数の交点を画定する、請求項1乃至5のいずれか1項に記載の医療用ステント。
- 前記複数の第1のフィラメントのうちの前記少なくとも1つの前記第1のらせん状経路は、前記周方向オフセットの第1の端部において前記複数の第2のフィラメントのうちの第1の1つの下を通過し、前記周方向オフセットの第2の端部において前記複数の第2のフィラメントのうちの第2の1つの下を通過する、請求項6に記載の医療用ステント。
- 前記複数の第1のフィラメントのうちの前記少なくとも1つの前記第1のらせん状経路は、前記第1の端部と前記第2の端部との間で互いに長手方向に離間された複数の周方向オフセットを含む、請求項1乃至7のいずれか1項に記載の医療用ステント。
- 前記複数の第1のフィラメントのうちの複数個の第1のフィラメントの前記第1のらせん状経路のそれぞれが、前記第1の端部と前記第2の端部との間に配置された周方向オフセットを含む、請求項1乃至8のいずれか1項に記載の医療用ステント。
- 医療用ステントを形成するためのマンドレルであって、
円筒体と、
前記円筒体から径方向外方に延びる複数の突出部と
を備え、
前記複数の突出部は、第1の方向に前記円筒体の周りをらせん状に延びる複数の第1のチャネルと、第2の方向に前記円筒体の周りをらせん状に延びる複数の第2のチャネルとを画定し、
前記複数の突出部のうちの少なくともいくつかには、前記円筒体の周りを周方向に延びる溝が形成されている、マンドレル。 - 前記複数の突出部のうちの前記形成された溝を含む前記少なくともいくつかは、前記複数の突出部のうちの残りの突出部よりも前記円筒体から径方向外方にさらに延びる隆起した突出部である、請求項10に記載のマンドレル。
- 前記溝は、前記円筒体の中心長手軸に対して実質的に垂直に配向される、請求項10または11に記載のマンドレル。
- 前記溝は、前記複数の第1のチャネルのうちの隣接する第1のチャネルを接続する、請求項10乃至12のいずれか1項に記載のマンドレル。
- 前記複数の突出部のうちの前記形成された溝を含む前記少なくともいくつかは、前記円筒体の周りに延びる突出部の周方向列を形成する、請求項10乃至13のいずれか1項に記載のマンドレル。
- 医療用ステントを製造する方法であって、
円筒体と、前記円筒体から径方向外方に延びる複数の突出部とを備えるマンドレルを使用する工程であって、前記複数の突出部は、第1の方向に前記円筒体の周りをらせん状に延びる複数の第1のチャネルと、第2の方向に前記円筒体の周りをらせん状に延びる複数の第2のチャネルとを画定し、前記複数の突出部のうちの少なくともいくつかには、前記円筒体の周りを周方向に延びる溝が形成されている、工程と、
前記複数の第1のチャネル内で前記マンドレルの周りに複数の第1のフィラメントを巻き付け、前記複数の第2のチャネル内で前記マンドレルの周りに複数の第2のフィラメントを巻き付けて、前記複数の第1のフィラメントと前記複数の第2のフィラメントとが織り合わされて前記医療用ステントの本体を画定するようにする工程と
を備え、
前記複数の第1のフィラメントのうちの少なくともいくつかは、前記複数の突出部のうちの前記形成された溝を含む前記少なくともいくつかの上に巻き付けられる、方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202062969498P | 2020-02-03 | 2020-02-03 | |
US62/969,498 | 2020-02-03 | ||
PCT/US2021/016244 WO2021158564A1 (en) | 2020-02-03 | 2021-02-02 | Stent, mandrel, and method for forming a stent with anti-migration features |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2023512302A true JP2023512302A (ja) | 2023-03-24 |
Family
ID=74798056
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2022547068A Pending JP2023512302A (ja) | 2020-02-03 | 2021-02-02 | ステント、マンドレル、および移動防止特徴を有するステントを形成するための方法 |
Country Status (8)
Country | Link |
---|---|
US (2) | US11707368B2 (ja) |
EP (1) | EP4099961A1 (ja) |
JP (1) | JP2023512302A (ja) |
KR (2) | KR102684751B1 (ja) |
CN (1) | CN115335008A (ja) |
AU (1) | AU2021215985B2 (ja) |
CA (1) | CA3169805A1 (ja) |
WO (1) | WO2021158564A1 (ja) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3735936B1 (en) * | 2014-10-09 | 2023-11-29 | Boston Scientific Scimed, Inc. | Mandrel and method of forming an expandable stent structure |
DE102019101238B8 (de) * | 2019-01-17 | 2020-08-06 | Stebo Sondermaschinenbau GmbH & Co. KG | Verfahren zum Herstellen eines geflochtenen Einfadenstents, Vorrichtung und Flechtkern hierfür sowie geflochtener Einfadenstent |
WO2021158564A1 (en) * | 2020-02-03 | 2021-08-12 | Boston Scientific Scimed, Inc. | Stent, mandrel, and method for forming a stent with anti-migration features |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH1170172A (ja) * | 1997-07-17 | 1999-03-16 | Schneider Europ Ag | 医療用ステント及びその製造方法 |
JP2016077884A (ja) * | 2014-10-21 | 2016-05-16 | テウン メディカル カンパニー リミテッド | 滑り止めステントの製造方法及びそれにより製造された滑り止めステント |
JP2017530786A (ja) * | 2014-10-09 | 2017-10-19 | ボストン サイエンティフィック サイムド,インコーポレイテッドBoston Scientific Scimed,Inc. | ドレナージ特徴部を有する膵臓ステント |
Family Cites Families (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5238004A (en) | 1990-04-10 | 1993-08-24 | Boston Scientific Corporation | High elongation linear elastic guidewire |
US5366504A (en) * | 1992-05-20 | 1994-11-22 | Boston Scientific Corporation | Tubular medical prosthesis |
US5662713A (en) | 1991-10-09 | 1997-09-02 | Boston Scientific Corporation | Medical stents for body lumens exhibiting peristaltic motion |
US5591197A (en) | 1995-03-14 | 1997-01-07 | Advanced Cardiovascular Systems, Inc. | Expandable stent forming projecting barbs and method for deploying |
US6520983B1 (en) | 1998-03-31 | 2003-02-18 | Scimed Life Systems, Inc. | Stent delivery system |
US6264689B1 (en) * | 1998-03-31 | 2001-07-24 | Scimed Life Systems, Incorporated | Low profile medical stent |
US6508803B1 (en) | 1998-11-06 | 2003-01-21 | Furukawa Techno Material Co., Ltd. | Niti-type medical guide wire and method of producing the same |
US6663663B2 (en) | 2001-05-14 | 2003-12-16 | M.I. Tech Co., Ltd. | Stent |
GB2379996B (en) | 2001-06-05 | 2004-05-19 | Tayside Flow Technologies Ltd | Flow means |
US7875068B2 (en) | 2002-11-05 | 2011-01-25 | Merit Medical Systems, Inc. | Removable biliary stent |
FR2847155B1 (fr) | 2002-11-20 | 2005-08-05 | Younes Boudjemline | Procede de fabrication d'un implant medical a structure ajouree et implant obtenu par ce procede |
US20040193141A1 (en) | 2003-02-14 | 2004-09-30 | Leopold Eric W. | Intravascular flow modifier and reinforcement device and deployment system for same |
US20050131515A1 (en) | 2003-12-16 | 2005-06-16 | Cully Edward H. | Removable stent-graft |
DE102004012981B4 (de) | 2004-03-16 | 2009-01-02 | Alveolus Inc. | Stent |
DE602005026162D1 (de) | 2004-10-25 | 2011-03-10 | Merit Medical Systems Inc | Hilfsmittel zum entfernen und versetzen eines stents |
DE102005019649A1 (de) | 2005-04-26 | 2006-11-02 | Alveolus Inc. | Knickfester Stent |
US7594928B2 (en) | 2006-05-17 | 2009-09-29 | Boston Scientific Scimed, Inc. | Bioabsorbable stents with reinforced filaments |
US8435283B2 (en) | 2007-06-13 | 2013-05-07 | Boston Scientific Scimed, Inc. | Anti-migration features and geometry for a shape memory polymer stent |
CA3010828A1 (en) | 2008-01-17 | 2009-07-23 | Boston Scientific Scimed, Inc. | Stent with anti-migration feature |
US7893564B2 (en) | 2008-08-05 | 2011-02-22 | Broadcom Corporation | Phased array wireless resonant power delivery system |
US8151682B2 (en) | 2009-01-26 | 2012-04-10 | Boston Scientific Scimed, Inc. | Atraumatic stent and method and apparatus for making the same |
US10398540B2 (en) | 2010-04-30 | 2019-09-03 | Boston Scientific Scimed, Inc. | Stent for repair of anastomasis surgery leaks |
EP3928807A1 (en) | 2011-01-28 | 2021-12-29 | Merit Medical Systems, Inc. | Electrospun ptfe coated stent and method of use |
US10285798B2 (en) | 2011-06-03 | 2019-05-14 | Merit Medical Systems, Inc. | Esophageal stent |
US8715334B2 (en) | 2011-07-14 | 2014-05-06 | Boston Scientific Scimed, Inc. | Anti-migration stent with quill filaments |
US9675473B2 (en) | 2011-12-29 | 2017-06-13 | Boston Scientific Scimed, Inc. | Stent with anti-migration features |
KR20140094144A (ko) | 2013-01-21 | 2014-07-30 | 주식회사 엠아이텍 | 이탈 방지용 스텐트, 제조 장치 및 그 제조 방법 |
CN105208977B (zh) | 2013-03-13 | 2020-06-09 | 波士顿科学国际有限公司 | 用于完全被覆盖支架的防止迁移组织锚固系统 |
US9265635B2 (en) | 2013-03-14 | 2016-02-23 | Boston Scientific Scimed, Inc. | Stent having removable anchoring element |
KR101498584B1 (ko) | 2013-05-15 | 2015-03-04 | 주식회사 스텐다드싸이텍 | 이동방지용 스텐트 |
WO2015038790A1 (en) | 2013-09-12 | 2015-03-19 | Boston Scientific Scimed, Inc. | Stent with anti-migration connectors |
US20160058585A1 (en) | 2014-08-29 | 2016-03-03 | Boston Scientific Scimed, Inc. | Medical devices including covers and methods for making and using same |
US10219921B2 (en) | 2014-10-02 | 2019-03-05 | Boston Scientific Scimed, Inc. | Controlled ingrowth feature for antimigration |
US10449064B2 (en) | 2015-02-12 | 2019-10-22 | Boston Scientific Scimed, Inc. | Stent with anti-migration feature |
US10307273B2 (en) | 2015-03-03 | 2019-06-04 | Boston Scientific Scimed, Inc. | Stent with anti-migration features |
US10682220B2 (en) | 2017-03-02 | 2020-06-16 | Boston Scientific Scimed, Inc. | Esophageal stent including an inner liner |
EP3658082A1 (en) | 2017-07-27 | 2020-06-03 | Boston Scientific Scimed Inc. | Adjustable mandrel for forming stent with anti-migration features |
WO2021158564A1 (en) | 2020-02-03 | 2021-08-12 | Boston Scientific Scimed, Inc. | Stent, mandrel, and method for forming a stent with anti-migration features |
-
2021
- 2021-02-02 WO PCT/US2021/016244 patent/WO2021158564A1/en unknown
- 2021-02-02 AU AU2021215985A patent/AU2021215985B2/en active Active
- 2021-02-02 CA CA3169805A patent/CA3169805A1/en active Pending
- 2021-02-02 CN CN202180024668.8A patent/CN115335008A/zh active Pending
- 2021-02-02 US US17/165,691 patent/US11707368B2/en active Active
- 2021-02-02 KR KR1020227030429A patent/KR102684751B1/ko active IP Right Grant
- 2021-02-02 KR KR1020247022961A patent/KR20240111019A/ko not_active Application Discontinuation
- 2021-02-02 EP EP21708830.1A patent/EP4099961A1/en active Pending
- 2021-02-02 JP JP2022547068A patent/JP2023512302A/ja active Pending
-
2023
- 2023-06-01 US US18/327,567 patent/US20230301808A1/en active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH1170172A (ja) * | 1997-07-17 | 1999-03-16 | Schneider Europ Ag | 医療用ステント及びその製造方法 |
JP2017530786A (ja) * | 2014-10-09 | 2017-10-19 | ボストン サイエンティフィック サイムド,インコーポレイテッドBoston Scientific Scimed,Inc. | ドレナージ特徴部を有する膵臓ステント |
JP2016077884A (ja) * | 2014-10-21 | 2016-05-16 | テウン メディカル カンパニー リミテッド | 滑り止めステントの製造方法及びそれにより製造された滑り止めステント |
Also Published As
Publication number | Publication date |
---|---|
AU2021215985B2 (en) | 2024-08-01 |
AU2021215985A1 (en) | 2022-08-18 |
WO2021158564A1 (en) | 2021-08-12 |
KR20240111019A (ko) | 2024-07-16 |
KR102684751B1 (ko) | 2024-07-12 |
CA3169805A1 (en) | 2021-08-12 |
US11707368B2 (en) | 2023-07-25 |
CN115335008A (zh) | 2022-11-11 |
EP4099961A1 (en) | 2022-12-14 |
US20210236309A1 (en) | 2021-08-05 |
KR20220137702A (ko) | 2022-10-12 |
US20230301808A1 (en) | 2023-09-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2023512302A (ja) | ステント、マンドレル、および移動防止特徴を有するステントを形成するための方法 | |
US11786355B2 (en) | Radial adjusting self-expanding stent with anti-migration features | |
US20220370217A1 (en) | Covered endoprosthesis with improved branch access | |
US11471311B2 (en) | Stent delivery system with reduced deployment force | |
US11564787B2 (en) | Stent with improved anti-migration properties | |
US20240130872A1 (en) | Stent system for maintaining patency of a body lumen | |
US11918496B2 (en) | Stent with improved deployment characteristics | |
US20230346577A1 (en) | Anti-migration stent | |
US20240033113A1 (en) | Anti-migration stent | |
US20240216153A1 (en) | Endoprosthesis for enhanced side branch access |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220927 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20230818 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230926 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20231213 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20240312 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240605 |